FDA Drug Information Soundcast in Clinical Oncology (D.I.S.C.O.) podcast

FDA D.I.S.C.O. Burst Edition: FDA approvals of Tivdak (tisotumab vedotin-tftv) for recurrent or metastatic cervical cancer with disease progression on or after chemotherapy, and Jakafi (ruxolitinib) for chronic graft-versus-host disease after failure of one or two lines of systemic therapy

0:00
4:59
Rewind 15 seconds
Fast Forward 15 seconds
Listen to a soundcast of the September 20 and 22, 2021, FDA approvals of Tivdak (tisotumab vedotin-tftv) for recurrent or metastatic cervical cancer with disease progression on or after chemotherapy, and Jakafi (ruxolitinib) for chronic graft-versus-host disease

More episodes from "FDA Drug Information Soundcast in Clinical Oncology (D.I.S.C.O.)"